HIGHLIGHTS
- who: Claudio Pulito from the Medicine, McMaster University, Hamilton, Ontario, Canada have published the article: Metformin-induced ablation of microRNA 21-5p releases Sestrin-1 and CAB39L antitumoral activities, in the Journal: (JOURNAL)
- what: The tumor-suppressor PTEN is a well-known target of the miR-21-5 , and thus the authors aimed at addressing whether modulation of PTEN may influence the conclusion in this experimental system. Starting from this observation, the authors focused here on the miR-21-5p, which the authors showed to be reduced by metformin in breast cancer cell lines, xenografted . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.